Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C | Q13936 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 10/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.35 |
| ▸ | HTR2A | P28223 | 7/20 | 0.35 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.34 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14774024 | 0.87 | CACNA1C (0.41) | CACNA1CHTR2CSLC6A4HTR2ACYP1A1 | |
| SCHEMBL14770531 | 0.83 | CACNA1C (0.40) | CACNA1CHTR2CSLC6A4HTR2ACYP1A1 | |
| SCHEMBL14770534 | 0.82 | SMN1; SMN2 (0.39) | CACNA1CCYP1A1CYP1A2CYP1B1ALKBH1 | |
| SCHEMBL14770538 | 0.82 | CACNA1C (0.40) | CACNA1CHTR2CSLC6A4HTR2ACYP1A1 | |
| SCHEMBL14770528 | 0.81 | NPC1 (0.42) | CACNA1CCYP1A1CYP1A2CYP1B1POLB | |
| SCHEMBL14770537 | 0.79 | CACNA1C (0.38) | CACNA1CHTR2CSLC6A4HTR2ACYP1A1 | |
| SCHEMBL14770530 | 0.79 | CACNA1C (0.38) | CACNA1CHTR2CSLC6A4HTR2ACYP1A1 | |
| SCHEMBL14770532 | 0.79 | AMY1A (0.38) | CACNA1CCYP1A1CYP1A2CYP1B1MAOB | |
| SCHEMBL14770527 | 0.79 | CACNA1C (0.38) | CACNA1CHTR2CSLC6A4HTR2ACYP1A1 | |
| SCHEMBL14770526 | 0.78 | CACNA1C (0.48) | CACNA1CHTR2CSLC6A4HTR2ACYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096531-B2 | Fused imidazole derivative | TOA EIYO LTD. (JP) | 2015-08-04 | — | — | US | disclosed |
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | TOA EIYO LTD. (JP) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | CACNA1E, CACNA1G, CACNA1A | CACNA1C 16/4885HTR2C 1506/4885SLC6A4 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.